Dr. Jonathan Bramson to be presenting at 3:20 p.m. CT on June 1.
At the IOBDLI Forum, Triumvira Scientific Founder and Acting Chief Scientific Officer, Dr. Jonathan Bramson, will provide an overview of the company’s T Cell-Antigen Coupler (TAC) technology, as well as updates on Triumvira’s lead drug, CD19-TAC01, which is targeted to enter clinical development in H1 2019 for the treatment of patients with CD19 positive B-cell malignancies. Dr. Bramson will be presenting at 3:20 p.m. CT on June 1.
Triumvira President and Chief Executive Officer, Dr. Paul Lammers available for private meetings June 4-5
At BIO International, Triumvira Immunologics President and Chief Executive Officer, Dr. Paul Lammers will be available for private meetings during the day on June 4-5 to discuss potential collaboration and licensing opportunities for the Company’s novel immuno-oncology platform T Cell-Antigen Coupler (TAC).
Triumvira will be presenting at ISCT 2018 – May 2-5, 2018 at the Palais des Congrès de Montréal in Montréal, QC, Canada
ISCT is the premier cell therapy translation society focused on pre-clinical, clinical and translational aspects of developing cell therapy products. As such, ISCT helps academic, government and biotech/pharma sectors transform research into practice and product.
ISCT 2018 is expected to draw over 1,600 delegates globally. The Annual Meeting will serve as the prime opportunity for you to network with experts within the global cell therapy arena.
Triumvira will be presenting at the Bloom Burton & Co. Healthcare Investor Conference on May 2 and 3, 2018 at the Sheraton Centre Toronto Hotel in Toronto, ON., Canada
This year, BBHIC will host approximately 60 of Canada’s premier publicly-traded and venture-backed private companies together with the most promising pre-venture companies in the healthcare industry. Our agenda includes company presentations, keynote sessions and panel discussions by industry leaders.